Paper155503
New drugs under clinical evaluation in the United States.
Carter SK. Cancer Chemother Pharmacol, 1978. Cited by 6 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. New drugs under clinical evaluation in the United States. Papers, record 155503. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/155503
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Aldehydes | |
| Altretamine | |
| Antineoplastic Agents, Phytogenic | |
| Carmustine | |
| Cisplatin | |
| Dianhydrogalactitol | |
| Drug Evaluation | |
| Humans | |
| Ifosfamide | |
| Maytansine | |
| Streptozocin | |
| Tegafur | |
| Trichothecenes |
Source PubMed
References60
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 5,347,922 | Clinical trials of a new antitumor polypeptide: neocarzinostatin (NCS). | Tohoku J Exp Med | 1969 | https://conductscience.org/library/papers/5347922 | PubMed |
| 2 | 1,203,889 | Clinical studies of Platinum Coordination compounds in the treatment of various malignant diseases. | Cancer Chemother Rep | 1975 | https://conductscience.org/library/papers/1203889 | PubMed |
| 3 | 4,203,933 | Platinum coordination complexes in cancer chemotherapy. | Naturwissenschaften | 1973 | https://conductscience.org/library/papers/4203933 | PubMed |
| 4 | 4,126,381 | Clinical trials of cis-diamminedichloroplatinum (NSC-119875). | Cancer Chemother Rep | 1973 | https://conductscience.org/library/papers/4126381 | PubMed |
| 5 | 4,652,589 | Pharmacologic and antitumor effects of 1,2:5,6-dianhydrogalactitol (NSC-132313). | Cancer Chemother Rep | 1972 | https://conductscience.org/library/papers/4652589 | PubMed |
| 6 | 5,051,663 | Results of treatment of malignant tumors with ftorafur. | Cancer | 1972 | https://conductscience.org/library/papers/5051663 | PubMed |
| 7 | 4,586,957 | Further experience with hexamethylmelamine (NSC-13875) in the treatment of carcinoma of the cervix. | Cancer Chemother Rep | 1973 | https://conductscience.org/library/papers/4586957 | PubMed |
| 8 | 4,548,188 | The chemical and biological effects of cis-dichlorodiammineplatinum (II), an antitumor agent, on DNA. | Proc Natl Acad Sci U S A | 1974 | https://conductscience.org/library/papers/4548188 | PubMed |
| 9 | 5,631,481 | Influence of the chemical structure on the biological endency of cytostatic compounds related to dibromomannitol. I. Structure-activity correlations. | Arzneimittelforschung | 1967 | https://conductscience.org/library/papers/5631481 | PubMed |
| 10 | 5,952,894 | Cytological studies on the effect of neocarzinostatin on HeLa cells. | J Antibiot (Tokyo) | 1966 | https://conductscience.org/library/papers/5952894 | PubMed |
| 11 | 5,804,737 | Toxicological research on substances from Fusarium nivale. 3. The structure of nivalenol and its monoacetate. | Tetrahedron Lett | 1969 | https://conductscience.org/library/papers/5804737 | PubMed |
| 12 | 6,062,296 | Metabolic pathway of cytostatic dibromohexitols. | Cancer Chemother Rep | 1967 | https://conductscience.org/library/papers/6062296 | PubMed |
| 13 | 4,674,442 | Polyribosomal breakdown in mouse fibroblasts (L-cells) by Fusarenon-X, a toxic principle isolated from Fusarium nivale. | Biochim Biophys Acta | 1972 | https://conductscience.org/library/papers/4674442 | PubMed |
| 14 | 1,248,396 | [cis-Diamino-dichloro-platinum (II) in the treatment of otherwise treatment-resistant malignant testicular teratoma (author's transl)]. | Dtsch Med Wochenschr | 1976 | https://conductscience.org/library/papers/1248396 | PubMed |
| 15 | 6,076,607 | The effect of mannitol-myleran and two new dibromo-hexitols on the metabolic activities of nucleic acids and proteins. I. | Biochem Pharmacol | 1967 | https://conductscience.org/library/papers/6076607 | PubMed |
| 16 | 5,631,482 | Influence of the chemical structure on the biological tendency of cytostatic compounds related to dibromomanitol. II. Mechanism of action. | Arzneimittelforschung | 1967 | https://conductscience.org/library/papers/5631482 | PubMed |
| 17 | 5,054,534 | Experience with ftorafur treatment in breast cancer. | Neoplasma | 1972 | https://conductscience.org/library/papers/5054534 | PubMed |
| 18 | 1,203,891 | Action of Cis-dichlorodiammineplatinum(II) (NSC-119875) at ehe cellular level. | Cancer Chemother Rep | 1975 | https://conductscience.org/library/papers/1203891 | PubMed |
| 19 | 5,908,739 | Neocarzinostatin (NSC-69856): an antitumor antibiotic effective against ascitic leukemia L1210 in mice. | Cancer Chemother Rep | 1966 | https://conductscience.org/library/papers/5908739 | PubMed |
| 20 | 4,447,935 | A mouse ependymoblastoma as an experimental model for screening potential antineoplastic drugs. | Cancer Chemother Rep 2 | 1974 | https://conductscience.org/library/papers/4447935 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/155503
GET https://conductscience.org/api/papers/v1/155503/references?page=2